8-K: Dyadic Reports 2025 Financials Amidst Commercial Growth

Dyadic International, Inc. announced its 2025 financial results, reporting increased net losses despite significant commercial and strategic partnership advancements.

Summary

• Net loss increased to $7.36 million in 2025, up from $5.81 million in 2024.
• Total revenue decreased to $3.09 million in 2025, down from $3.50 million in 2024.
• Cash, cash equivalents, restricted cash, and investment-grade securities were $8.59 million as of December 31, 2025, a decrease from $9.29 million in 2024.
• Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals, with Dyadic eligible for a share of profits from product sales.
• Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I.
• Signed an OEM distribution agreement with IBT Bioservices to commercialize recombinant DNase I and transferrin through global channels.
• Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin, including funded development, milestones, and potential revenue participation.
• Inzymes announced plans to commercialize recombinant non-animal bovine chymosin in 2026 after meeting development milestones.
• Grant revenue increased to $1.86 million in 2025 from the Gates Foundation and CEPI, partially offsetting declines in other revenue streams.
• Loss from operations increased to $7.19 million in 2025, compared to $5.90 million in 2024.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the company made significant commercial and strategic progress with new partnerships and product launches, the financial results show increased losses and declining revenue, indicating continued burn and a challenging path to profitability.

Positives

• Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals, with Dyadic eligible to receive a share of profits from product sales.
• Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership.
• Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channels.
• Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin for global nutrition markets, which includes funded development, milestones, and potential revenue participation.
• Inzymes announced plans to commercialize recombinant non-animal bovine chymosin in 2026 after meeting development milestones and making an additional milestone payment to Dyadic.
• Grant revenue increased to $1.86 million in 2025 from the Gates Foundation and CEPI, demonstrating success in securing non-dilutive funding for biopharmaceutical programs.
• Secured a non-exclusive CRISPR/Cas9 license agreement with ERS Genomics to expand genetic engineering capabilities and accelerate strain optimization.
• Rebranded as Dyadic Applied BioSolutions and launched a redesigned corporate website to better support product commercialization and customer engagement.
• Engaged Intralink to expand commercial development activities in Japan and South Korea, facilitating market entry for animal-free proteins.
• A study published in Vaccine (October 24, 2025) reported successful production and characterization of the SARS-CoV-2 spike protein using Dyadic's C1 expression platform.

Negatives

• Net loss for the year ended December 31, 2025, was $7.36 million, an increase from $5.81 million in 2024.
• Basic and diluted net loss per common share increased to $(0.23) in 2025 from $(0.20) in 2024.
• Total revenue for 2025 decreased to $3.09 million from $3.50 million in the prior year.
• Cash, cash equivalents, restricted cash, and investment-grade securities decreased to $8.59 million as of December 31, 2025, from $9.29 million as of December 31, 2024.
• Research and development revenue decreased by $638,000 in 2025, reflecting fewer active collaborations.
• License and milestone revenue significantly decreased to $265,000 in 2025 from $1.89 million in 2024.
• Loss from operations increased to $7.19 million in 2025, compared to $5.90 million in 2024.

Risks

• History of net losses.
• Market and regulatory acceptance of microbial protein production platforms and other technologies.
• Failure to commercialize microbial protein production platforms or other technologies.
• Competition, including from alternative technologies.
• Results of nonclinical studies and clinical trials.
• Capital needs.
• Changes in global economic and financial conditions.
• Reliance on information technology.
• Dependence on third parties.
• Government regulations and environmental, social, and governance issues.
• Intellectual property risks.
• Ability to comply with the listing standards of the Nasdaq Stock Market LLC.

Future Outlook

Dyadic remains committed to accelerating commercialization of its expanding portfolio of animal-free proteins and enzymes, providing partners with scalable manufacturing solutions, and increasing the number of products and channels through which it can generate long-term value. The company anticipates broadening both partner-led and internal development programs focused on non-animal dairy proteins, selected food and nutrition enzymes, and related baking and brewing enzyme applications. Inzymes plans to commercialize recombinant non-animal bovine chymosin in 2026.

Management Comments

• "During 2025 and into early 2026, we have continued to execute our strategy to transition Dyadic into a commercially driven organization by broadening market access, introducing new products, and deepening our partner network across life sciences, food and nutrition, and bioindustrial sectors." Joe Hazelton, President and Chief Operating Officer.
• "The commercial launch of AlbuFree DX with Proliant, our expanded collaboration and product launch with Fermbox, our OEM distribution agreement with IBT Bioservices, our development and commercialization agreement with BRIG BIO, and ongoing progress with Inzymes demonstrate the tangible progress we are making to leverage our microbial production platforms to produce products thus enabling recurring revenue streams." Joe Hazelton.
• "We remain committed to accelerating commercialization of our expanding portfolio of animal-free proteins and enzymes, providing our partners with scalable manufacturing solutions, and increasing the number of products and channels through which Dyadic can generate long-term value." Joe Hazelton.

Industry Context

StockSavvy.ai notes that Dyadic's focus on animal-free recombinant proteins and enzymes aligns with growing consumer and industry demand for sustainable, ethical, and scalable alternatives in life sciences, food and nutrition, and bioindustrial sectors. The company's strategic partnerships and product commercialization efforts position it to capitalize on the expanding market for alternative protein production technologies, particularly in areas like cell culture media, diagnostics, and non-animal dairy.

Comparison to Industry Standards

• The development of low-cost monoclonal antibodies targeting RSV and malaria, with early data demonstrating comparability to CHO-derived antibodies, suggests Dyadic's C1 platform is competitive with established mammalian cell expression systems like CHO cells, which are a global benchmark for biopharmaceutical production.
• The commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals positions Dyadic in the growing market for animal-free components, competing with traditional plasma-derived albumin and other recombinant alternatives.
• The development of non-animal bovine chymosin and alpha-lactalbumin places Dyadic in the emerging precision fermentation dairy market, where companies like Perfect Day and Remilk are also developing animal-free dairy proteins.

Related Party Transactions

• Interest expense related party: $(123,843) in 2025 compared to $(139,829) in 2024.
• Convertible notes, net of issuance costs related party: $2,063,740 as of December 31, 2025, compared to $1,065,876 as of December 31, 2024.

Stakeholder Impact

• Shareholders: Increased net loss and declining cash position could negatively impact shareholder value, while new commercial agreements and product launches offer potential for future growth.
• Partners (Proliant, Fermbox, IBT, BRIG Bio, Inzymes): Benefit from Dyadic's production platforms and expanded collaboration, leading to new product commercialization and market access.
• Employees: Continued internal research activities and strategic expansion suggest ongoing employment opportunities, though financial losses could pose long-term concerns.
• Customers: Benefit from new animal-free protein and enzyme products for various applications (life sciences, food, bioindustrial).
• Creditors: The increase in convertible notes (including related party) and overall liabilities, coupled with increased losses, could raise concerns about the company's ability to service debt, although the cash position is still substantial for a company of this size.

Next Steps

• Accelerate commercialization of the expanding portfolio of animal-free proteins and enzymes.
• Increase the number of products and channels for long-term value generation.
• Broaden partner-led and internal development programs for non-animal dairy proteins, food/nutrition enzymes, and baking/brewing enzyme applications.
• Inzymes plans to launch recombinant non-animal bovine chymosin in 2026.
• Continue optimization and characterization efforts for recombinant human lactoferrin.
• Advance collaborations with global health organizations, academic institutions, and industry partners for vaccine and antibody development.
• Continue preclinical evaluation of H5 antigen and review additional diagnostic applications under the CEPI/FBS program.
• Advance malaria vaccine candidates toward potential clinical selection under NIAID/NIH (LMIV) program.
• Continue development of prefusion RSV and multivalent respiratory vaccine antigens with The Scripps Research Institute.
• Participate in the $12.4 million filovirus vaccine program with AdaptVac.
• Participate in the 170 million EU-backed pandemic preparedness initiative (European Vaccines Hub).
• Evaluate C1 for MERS vaccine antigen production with Uvax Bio.
• Continue rabies vaccine development program with Rabian, with potential future milestones, royalties, and equity value.
• Host an earnings call on March 25, 2026, at 5:00 pm ET.

Key Dates

Recommendation

While Dyadic has demonstrated significant progress in commercializing its technology through new partnerships and product launches, the financial results for 2025 show a worsening net loss and declining revenue, alongside a reduction in cash reserves. The company is clearly in a transition phase, investing heavily in R&D and commercialization efforts, which is reflected in the increased operational losses. The long-term potential from its proprietary platforms and diverse product pipeline is notable, but the current financial performance indicates that profitability remains a distant goal. A "hold" recommendation is appropriate as investors should monitor the execution of these commercial strategies and the impact on future financial statements before making a more definitive investment decision.

Keywords

biotechnology, animal-free proteins, enzymes, C1 expression system, Dapibus platform, recombinant human albumin, AlbuFree DX, DNase I, transferrin, alpha-lactalbumin, chymosin, cell culture, vaccines, monoclonal antibodies, Gates Foundation, CEPI, biopharmaceuticals, food and nutrition, bioindustrial, CRISPR, genetic engineering, NASDAQ: DYAI